237 related articles for article (PubMed ID: 20129499)
1. Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury.
Vink R; van den Heuvel C
Neurotherapeutics; 2010 Jan; 7(1):74-80. PubMed ID: 20129499
[TBL] [Abstract][Full Text] [Related]
2. Substance P in traumatic brain injury.
Donkin JJ; Turner RJ; Hassan I; Vink R
Prog Brain Res; 2007; 161():97-109. PubMed ID: 17618972
[TBL] [Abstract][Full Text] [Related]
3. Inflammation in acute CNS injury: a focus on the role of substance P.
Corrigan F; Vink R; Turner RJ
Br J Pharmacol; 2016 Feb; 173(4):703-15. PubMed ID: 25827155
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke.
Turner R; Vink R
Timely Top Med Cardiovasc Dis; 2007 Oct; 11():E24. PubMed ID: 18297137
[TBL] [Abstract][Full Text] [Related]
5. NK1 receptor blockade is ineffective in improving outcome following a balloon compression model of spinal cord injury.
Leonard AV; Thornton E; Vink R
PLoS One; 2014; 9(5):e98364. PubMed ID: 24859234
[TBL] [Abstract][Full Text] [Related]
6. The Role of Substance P Within Traumatic Brain Injury and Implications for Therapy.
Safwat A; Helmy A; Gupta A
J Neurotrauma; 2023 Aug; 40(15-16):1567-1583. PubMed ID: 37132595
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments.
Donkin JJ; Vink R
Curr Opin Neurol; 2010 Jun; 23(3):293-9. PubMed ID: 20168229
[TBL] [Abstract][Full Text] [Related]
8. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
[TBL] [Abstract][Full Text] [Related]
9. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury.
Donkin JJ; Nimmo AJ; Cernak I; Blumbergs PC; Vink R
J Cereb Blood Flow Metab; 2009 Aug; 29(8):1388-98. PubMed ID: 19436311
[TBL] [Abstract][Full Text] [Related]
10. The potential for substance P antagonists as anti-cancer agents in brain tumours.
Harford-Wright E; Lewis KM; Vink R
Recent Pat CNS Drug Discov; 2013 Apr; 8(1):13-23. PubMed ID: 23477306
[TBL] [Abstract][Full Text] [Related]
11. Substance P antagonists as a novel intervention for brain edema and raised intracranial pressure.
Gabrielian L; Helps SC; Thornton E; Turner RJ; Leonard AV; Vink R
Acta Neurochir Suppl; 2013; 118():201-4. PubMed ID: 23564132
[TBL] [Abstract][Full Text] [Related]
12. The Role of Neurogenic Inflammation in Blood-Brain Barrier Disruption and Development of Cerebral Oedema Following Acute Central Nervous System (CNS) Injury.
Sorby-Adams AJ; Marcoionni AM; Dempsey ER; Woenig JA; Turner RJ
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817088
[TBL] [Abstract][Full Text] [Related]
13. A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke.
Turner RJ; Helps SC; Thornton E; Vink R
Brain Res; 2011 Jun; 1393():84-90. PubMed ID: 21466790
[TBL] [Abstract][Full Text] [Related]
14. A substance P antagonist reduces axonal injury and improves neurologic outcome when administered up to 12 hours after traumatic brain injury.
Donkin JJ; Cernak I; Blumbergs PC; Vink R
J Neurotrauma; 2011 Feb; 28(2):217-24. PubMed ID: 21175297
[TBL] [Abstract][Full Text] [Related]
15. Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.
Harford-Wright E; Lewis KM; Ghabriel MN; Vink R
PLoS One; 2014; 9(5):e97002. PubMed ID: 24818961
[TBL] [Abstract][Full Text] [Related]
16. Advancing drug therapy for brain tumours: a current review of the pro-inflammatory peptide Substance P and its antagonists as anti-cancer agents.
Mander K; Harford-Wright E; Lewis KM; Vink R
Recent Pat CNS Drug Discov; 2014; 9(2):110-21. PubMed ID: 25386916
[TBL] [Abstract][Full Text] [Related]
17. Changes in substance P and NK1 receptor immunohistochemistry following human spinal cord injury.
Leonard AV; Manavis J; Blumbergs PC; Vink R
Spinal Cord; 2014 Jan; 52(1):17-23. PubMed ID: 24216617
[TBL] [Abstract][Full Text] [Related]
18. Substance P does not play a critical role in neurogenic inflammation in the rat masseter muscle.
Ro JY; Zhang Y; Nies M
Brain Res; 2005 Jun; 1047(1):38-44. PubMed ID: 15885663
[TBL] [Abstract][Full Text] [Related]
19. C-FOS expression in the rat brain in response to substance P and neurokinin B.
Spitznagel H; Baulmann J; Blume A; Unger T; Culman J
Brain Res; 2001 Oct; 916(1-2):11-21. PubMed ID: 11597586
[TBL] [Abstract][Full Text] [Related]
20. Substance P and the Neurokinin-1 Receptor: The New CRF.
Schank JR; Heilig M
Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
